Laboratorios Farmaceuticos Rovi, S.A. (LON:0ILL)

Market Cap	2.45B
Revenue (ttm)	642.04M
Net Income (ttm)	117.14M
Shares Out	n/a
EPS (ttm)	2.29
PE Ratio	20.92
Forward PE	20.73
Dividend	0.75 (1.35%)
Ex-Dividend Date	Jul 8, 2024

Volume	9,454
Average Volume	11,581
Open	55.60
Previous Close	55.20
Day's Range	55.50 - 55.95
52-Week Range	45.58 - 90.05
Beta	0.44
RSI	69.98
Earnings Date	Jul 25, 2025

About LON:0ILL

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1946
• Employees: 2,197
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ILL

Financial Performance

In 2024, LON:0ILL's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.

Financial numbers in EUR